William R. Miller

Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA.

Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT.

ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ.

Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ.

Opera Orchestra of New York, Inc. engages in the performance of opera in a concert form. It focuses solely on the fit between the voice and the role of artists. The company was founded by Eve Queler and is headquartered in New York, NY.

Metropolitan Opera Association, Inc. organizes and performs opera shows in its residence at the Lincoln Center of Performing Arts. The firm offers services in association with sponsors, such as Texaco. It produces radio, television and compact disk recordings of the performances and distributes them around the world. The company was founded in 1883 and is headquartered in New York, NY.